RxDoctor Payments DataLook up a doctor →

Kent Rollins, MD

Urology · Richmond, VANPI 1508821695

Payments from drug & device makers

$15,764in general payments, 2019–2025

Across 791 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$2K
  • AbbVie$1K
  • Bayer$1K
  • Blue Earth Diagnostics$1K
  • Pfizer$984
  • Astellas Pharma US Inc$911
  • plus $9K from 43 others

What the payments were for

  • Food & beverage$15,750100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,764 in reported general payments places this provider in the 80th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$394,236
Medicare patients
1,179
Services billed
26,618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide12$164,527
XtandiEnzalutamide16$152,463
OrgovyxRelugolix20$52,014
GemtesaVibegron75$45,302
MyrbetriqMirabegron42$32,844
Tamsulosin Hcl1,178$18,507
Abiraterone Acetate21$12,194
Tadalafil37$6,483
Testosterone27$3,558
Finasteride239$3,208
Silodosin24$2,775
Trospium Chloride58$2,160
NitrofurantoinNitrofurantoin Macrocrystal45$1,682
Trimethoprim29$1,559
Dutasteride45$1,416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$911$185,30758 claims
BayerNubeqa$1,162$164,52712 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$729$97,31695 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$28$12,19421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 300 urology providers in Virginia.

Other urology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →